Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan

Bibliography

• Patient Registration Committee, Japanese Society For Dialysis Therapy. An overview of regular dialysis treatment in Japan (as of 31 December 2003). Ther Apher Dial 2005;9:431-58
   PubMedGoogle Scholar
• Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:34-8
   PubMed Web of Science ®Google Scholar
• Iseki K, Shinzato T, Nagura Y, Akiba T. Factors influencing long-term survival in patients on chronic dialysis. Clin Exp Nephrol 2004;8:89-97
   PubMedGoogle Scholar
• Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997;29:496-502
   PubMed Web of Science ®Google Scholar
• De Boer IH, Gorodetskaya I, Young B, et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002;13:2762-9
   PubMed Web of Science ®Google Scholar
• Amann K, Gross ML, London GM, et al. Hyperphosphatemia – a silent killer of patients with renal failure? Nephrol Dial Transplant 1999;14:2085-7
   PubMed Web of Science ®Google Scholar
• Locatelli F, Cannata-Andia JB, Drueke T, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphatemia. Nephrol Dial Transplant 2002;17:723-31
   PubMed Web of Science ®Google Scholar
• Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18
   PubMed Web of Science ®Google Scholar
• Imanishi Y, Tahara H, Palanisamy N, et al. Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Am Soc Nephrol 2002;13:1490-8
   PubMedGoogle Scholar
• Chattopadhyay N, Brown EM. Role of calcium-sensing receptor in mineral ion metabolism and inherited disorders of calcium-sensing. Mol Metab 2006;89:189-202
   Google Scholar
• Kazama JJ, Sato F, Omori K, et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005;67:1120-5
   PubMed Web of Science ®Google Scholar
• Nakanishi S, Kazama JJ, Nii-Kono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005;67:1171-8
   PubMed Web of Science ®Google Scholar
• Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF-23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-5
   PubMed Web of Science ®Google Scholar
• Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701
   PubMed Web of Science ®Google Scholar
• Tozawa M, Iseki K, Iseki C, et al. Evidence for elevated pulse pressure in patients on chronic hemodialysis – a case control study. Kidney Int 2002;62:2195-201
   PubMedGoogle Scholar
• Kawagishi T, Nishizawa Y, Konishi T, et al. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 1995;48:820-6
   PubMed Web of Science ®Google Scholar
• Ishimura E, Taniwaki H, Tabata T, et al. Cross-sectional association of serum phosphate with carotid intima-medial thickness in hemodialysis patients. Am J Kidney Dis 2005;45:859-65
   PubMedGoogle Scholar
• Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83
   PubMed Web of Science ®Google Scholar
• Ganesh SH, Stack AG, Levin NW, et al. Association of elevated serum PO4, Ca × PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8
   PubMed Web of Science ®Google Scholar
• Massry SG. Is parathyroid hormone a uremic toxin? Nephron 1977;19:125-30
   PubMedGoogle Scholar
• Aman K, Ritz E, Wiest G, et al. A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 1994;4:1814-9
   PubMedGoogle Scholar
• Akiba T, Marumo F, Owada A, et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998;32:238-46
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorous and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17
   PubMed Web of Science ®Google Scholar
• Slinin Y, Foley RN, Collins AJ. Calcium, phosphorous, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-93
   PubMed Web of Science ®Google Scholar
• Akizawa T, Kinugasa E, Akiba T, et al. Incidence and clinical characteristics of hypoparathyroidism in dialysis patients. Kidney Int 1997;62(Suppl):S72-4
   Google Scholar
• Tamashiro M, Iseki K, Sunagawa O, et al. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 2001;38:64-9
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke S, Raggi P; For The Treat To Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
   PubMed Web of Science ®Google Scholar
• Matsuoka M, Iseki K, Fujimoto N, et al. Significance of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004;8:54-8
   PubMedGoogle Scholar
• Fujimoto N, Iseki K, Tokuyama K, et al. Significance of coronary artery calcification score (CACS) for the detection of coronary artery disease (CAD) in chronic dialysis patients. Clin Chim Acta 2006;367:98-102
   PubMedGoogle Scholar
• Blacher J, Guerin AP, Pannier B, et al. Arterial calcification, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-42
   PubMed Web of Science ®Google Scholar
• Morena M, Terrier N, Jaussent I, et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol 2006;17:262-70
   PubMed Web of Science ®Google Scholar
• Vega D, Maalouf NM, Sakhaee K. The role of RANK/RANKL/OPG: clinical implications. J Clin Endocrinol Metab 2007;92:4514-21
   PubMed Web of Science ®Google Scholar
• Baud'huin M, Lamoureux F, Duplomb L, et al. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 2007;64:2334-50
   PubMed Web of Science ®Google Scholar
• Tanaka H, Shiohira Y, Uezu Y, et al. Metabolic syndrome and chronic kidney disease in Okinawa, Jpn Kidney Int 2006;69:369-74
   PubMed Web of Science ®Google Scholar
• Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21-8
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease; a statement from the American Heart Association comments on kidney in cardiovascular disease, high blood pressure research, clinical cardiology and epidemiology and prevention. Circulation 2003;108:2154-69
   PubMed Web of Science ®Google Scholar
• Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 1993;44:115-9
   PubMedGoogle Scholar
• Iseki K, Miyasato F, Tokuyama K, et al. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int 1997;51:1212-7
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kilpatrick RD, Mcallister CJ, et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population. Hypertension 2005;45:811-7
   PubMedGoogle Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and diseases in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):S1-202
   PubMedGoogle Scholar
• Slatopolsky EA, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984;74:2136-43
   PubMed Web of Science ®Google Scholar
• Tsukamoto Y, Nomura M, Marumo F. Pharmacological parathyroidectomy by oral 1,25 (OH)2D3 pulse therapy. Nephron 1989;51:130-1
   PubMedGoogle Scholar
• Tsukamoto Y, Hanaoka M, Matsuo T, et al. Effects of 22-oxacalcitol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000;35:458-64
   PubMed Web of Science ®Google Scholar
• UptoDate 2007; Cinacalcet: Drug information.
   Google Scholar
• Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997;29:641-9
   PubMed Web of Science ®Google Scholar
• Moe SM, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003;23:369-79
   PubMed Web of Science ®Google Scholar
• Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 2001;60:472-9
   PubMedGoogle Scholar
• Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004;9:179-87
   Google Scholar
• Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315:157-61
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999;14:2907-14
   PubMed Web of Science ®Google Scholar
• Bleyer AJ, Burke SK, Dillon M, Garrett B. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999;33:694-701
   PubMed Web of Science ®Google Scholar
• Slatopolsky E. New developments in hyperphosphatemia management. J Am Soc Nephrol 2003;14:S297-9
   Google Scholar
• Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429-36
   PubMed Web of Science ®Google Scholar
• Koiwa F, Onoda N, Kato H, et al. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial 2005;9:340-6
   PubMed Web of Science ®Google Scholar
• Finn WF, Joy MS, Hladik G; The Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorous in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004;62:193-201
   PubMed Web of Science ®Google Scholar
• D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003;63(Suppl 85):S73-8
   Web of Science ®Google Scholar
• Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005;68:2809-13
   PubMed Web of Science ®Google Scholar
• Broan AJ, Ritter CR, Finch LJ, et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989;84:728-32
   PubMedGoogle Scholar
• Slatopolsky E, Finch LJ, Ritter CR, et al. A new analogue of calcitriol, 19-nor-1, 25(OH)2 D2, suppresses parathyroid hormone in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995;26:852-60
   PubMed Web of Science ®Google Scholar
• Tan Au JR, Levine BS, Mazess RB, et al. Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997;51:317-23
   PubMedGoogle Scholar
• Fukagawa M, Okazaki R, Takano K, et al. Regression of parathyroid hyperplasia by calcitriol – pulse therapy in patients on long-term dialysis. N Engl J Med 1990;323:421-2
   PubMed Web of Science ®Google Scholar
• Shiizaki K, Hatamura I, Negi S, et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 2003;64:992-1003
   PubMed Web of Science ®Google Scholar
• Teng M, Wolf M, Lowrie E, Ofsthun N. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56
   PubMed Web of Science ®Google Scholar
• Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001;38(Suppl 5):S45-50
   PubMed Web of Science ®Google Scholar
• Sprague SM, Lerma E, McCormmick D, et al. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001;38:S51-6
   PubMed Web of Science ®Google Scholar
• Tsukamoto Y, Nomura M, Takahashi Y, et al. The ‘oral 1,25-dihydroxyvitamin D3 pulse therapy’ in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1991;57:23-8
   PubMedGoogle Scholar
• Gallieni M, Brancaccio D, Padovese P, et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 1992;42:1191-208
   PubMedGoogle Scholar
• Lemmila S, Saha H, Virtanen V, et al. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 1998;18:404-10
   PubMed Web of Science ®Google Scholar
• Wu J, Garami M, Cheng T, et al. 1,25(OH)2 vitamin D3 and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996;97:1577-88
   PubMed Web of Science ®Google Scholar
• Park CW, Oh YS, Shin YS, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999;33:73-81
   PubMed Web of Science ®Google Scholar
• Raine AE, Bedford L, Simpson AWM, et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993;43:700-5
   PubMedGoogle Scholar
• Mohtai M, Yamamoto T. Smooth muscle cell proliferation in the rat coronary artery induced by vitamin D. Atherosclerosis 1987;63:193-202
   PubMedGoogle Scholar
• Carthy EP, Yamashita W, Hsu A, Ooi BS. 1,25-Dihydroxy-vitamin D3 and rat vascular smooth muscle cell growth. Hypertension 1989;13:954-9
   PubMed Web of Science ®Google Scholar
• Fukagawa M, Kitaoka M, Tominaga Y, et al. Selective percutaneous ethanol injection therapy (PEIT) of the parathyroid in chronic dialysis patients – the Japanese strategy. Japanese Working Group on PEIT of Parathyroid, Tokyo, Japan. Nephrol Dial Transplant 1999;14:2574-7
   PubMed Web of Science ®Google Scholar
• Kakuata T, Fukagawa M, Fujisaki T, et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999;33:1091-9
   PubMedGoogle Scholar
• Tominaga Y, Kitaoka M, Fukagawa M, et al. Guidelines on selective parathyroid PEIT (provisional). J Jpn Soc Dial Ther 1999;32:1099-103
   Google Scholar
• Tominaga Y, Kitaoka M, Fukagawa M, et al. Guidelines on selective PEIT. J Jpn Soc Dial Ther 2000;33:1343-5
   Google Scholar
• De Barros Gueiros JE, Cristina M, Gerhard CR, et al. Percutaneous ethanol (PEIT) and calcitriol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism. Nephrol Dial Transplant 2004;19:657-63
   PubMedGoogle Scholar
• Tanaka M, Itoh K, Matsushita K, et al. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium × phosphorus product in secondary hyperparathyroidism. Nephron Clin Pract 2005;13:1-7
   Google Scholar
• Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potent treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575-83
   PubMedGoogle Scholar
• Block GA, Martin KJ, De Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25
   PubMed Web of Science ®Google Scholar
• Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:760-71
   PubMed Web of Science ®Google Scholar
• Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16:800-7
   PubMed Web of Science ®Google Scholar
• Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800
   PubMed Web of Science ®Google Scholar
• Szczech LA. The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials. Kidney Int 2004;66(Suppl 90):S46-8
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Harnett D, et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996;16:386-93
   PubMed Web of Science ®Google Scholar
• Drueke TB, Rostand SG. Progression of vascular calcification in uraemic patients: can it be stopped? Nephrol Dial Transplant 2002;17:1365-8
   PubMedGoogle Scholar
• Touam M, Menoyo V, Attaf D, et al. High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism. Kidney Int 2005;67:2065-8
   PubMedGoogle Scholar
• Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004;65:1099-104
   PubMed Web of Science ®Google Scholar
• Holgado R, Haire H, Ross D, et al. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res 2000;15:927-35
   PubMedGoogle Scholar
• Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int 1999;73(Suppl):S14-9
   Google Scholar
• Gutwiller JP, Schneditz D, Huber AR, et al. Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose. Nephrol Dial Transplant 2002;17:1037-44
   PubMedGoogle Scholar
• Ratanarat R, Brendolan A, Volker G, et al. Phosphate kinetics during different dialysis modalities. Blood Purify 2005;23:83-90
   PubMed Web of Science ®Google Scholar
• Jean G, Chazot C, Charra B. Hyperphosphatemia and related mortality: Editorial review. Nephrol Dial Transplant 2006;21:273-80
   PubMedGoogle Scholar
• Fukagawa M, Akizawa T. How to apply and adapt international guidelines on bone metabolism ad disease to the management of Japanese dialysis patients. Ther Apher Dial 2005;9:1-2
   PubMedGoogle Scholar
• Rothmund M. Surgical treatment of secondary hyperparathyroidism: indication, operative management and results. Prog Surg 1986;18:186-205
   Google Scholar
• Tokuyama K, Iseki K, Yoshi S, et al. An epidemiologic analysis of parathyroidectomy in chronic dialysis patients. The Okinawa Dialysis Study Group. Nippon Jinzo Gakkai Shi 1996;38:309-13
   PubMedGoogle Scholar
• Malberti F, Marcelli D, Conte F, et al. Parathyroidectomy in patients on renal replacement therapy: an epidemiologic study. J Am Soc Nephrol 2001;12:1242-8
   PubMed Web of Science ®Google Scholar
• Foley RN, Li S, Liu J, et al. The fall and rise of parathyroidectomy in US hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005;16:210-8
   PubMed Web of Science ®Google Scholar
• Iseki K, Nakai S, Shinzato T, et al. Increasing difference between sexes in the incidence of chronic dialysis patients in Japan. Ther Apher Dial 2005;9:407-11
   PubMed Web of Science ®Google Scholar
• Iseki K, Uehara H, Nishime K, et al. Impact of the initial levels of laboratory variables on survival in chronic dialysis patients. Am J Kidney Dis 1996;28:541-8
   PubMedGoogle Scholar
• Slatopolsky E, Brown A, Dusso A. Calcium, phosphorus and vitamin D disorders in uremia. Contrib Nephrol 2005;149:261-71
   PubMedGoogle Scholar
• Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-48
   PubMed Web of Science ®Google Scholar
• Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-9
   PubMed Web of Science ®Google Scholar
• Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int 1992;41:1286-91
   PubMed Web of Science ®Google Scholar
• Tozawa M, Iseki K, Iseki C, et al. Analysis of drug prescription in patients on chronic hemodialysis. Nephrol Dial Transplant 2002;17:1819-24
   PubMed Web of Science ®Google Scholar
• Nakai S, Akiba K, Kazama J, et al. Effects of serum levels of calcium, phosphorous, and intact PTH on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 2008;In press
   Google Scholar